Lexaria signs material transfer agreement with PegBio to test DehydraTECH with GLP-1 molecule
LEXX•Agreement to test DehydraTECH with PegBio's GLP-1 molecule
Lexaria entered a material transfer agreement with PegBio to test DehydraTECH with PegBio’s proprietary GLP-1 molecule.
PegBio will supply the molecule for DehydraTECH processing, followed by animal pharmacokinetic studies to assess performance.
Results could inform follow-on business decisions, including potential technology licensing or other commercial arrangements.
PegBio’s lead GLP-1 product won China approval in November 2025 as an injectable treatment.
